Korean J Sports Med.  2011 Dec;29(2):105-111. 10.5763/kjsm.2011.29.2.105.

Effects of Beta-Blocker on Cardiorespiratory Fitness Factors and Blood Lipid of Patients with Acute Coronary Syndrome

• Kim C
• Kim CH
• Kim YJ

• KMID: 1987190
• DOI: http://doi.org/10.5763/kjsm.2011.29.2.105

Abstract

The purpose of this study is to investigate effects of beta-blocker prescribed at the beginning of cardiac rehabilitation exercise for patients with acute coronary syndrome (ACS) on cardiorespiratory fitness factors and blood lipid at the 6th and the 14th week. The subjects of this study were patients (beta blocker group: n=20, non-beta blocker group: n=22) who underwent internal procedure because of ACS. The patients were conducted of exercise stress test and blood lipid before cardiac rehabilitation (the first period), were additionally prescribed of beta-blocker by cardiologist at the first week, and were conducted of exercise stress test and blood lipid at the 6th (the second period) and the 14th (the third period) week. Based on the results of this study, rest heart rate, maximal rate pressure product, sub-maximal rate pressure product, time and rate of perceived exertion showed no significant differences between groups, but peakVO2 showed interaction effect between treatment and period. All the items of blood lipid showed no differences between the groups. Conclusively, the group of beta-blocker administration showed negative effect on increase in peakVO2 at the 6th week but had positive effect at the 14th week. Meanwhile, beta-blocker did not affect blood lipid. Therefore, when patients with cardiovascular disease were additionally administered of beta-blocker at earlier period of cardiac rehabilitation, it may be needed of training time of at least six weeks to increase peakVO2.

Keyword

Beta-blocker; Cardiorespiratory fitness; Cardiac rehabilitation; Cardiovascular disease

MeSH Terms

Acute Coronary Syndrome
Cardiovascular Diseases
Exercise Test
Heart Rate
Humans

Reference

References

1. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet. 2005; 366:1545–53.

2. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007; 370:591–603.

3. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Manage-ment of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008; 117:296–329.

4. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet. 2005; 366:1622–32.

5. Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol. 1998; 32:634–40.

6. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and longterm acute myocardial infarction intervention trials. Am J Cardiol. 1986; 57:43F–9F.

7. Cohn JN. Clinical implications of the hemodynamic effects of beta blockade. Am J Cardiol. 1985; 55:125D–8D.

8. Wilmore JH, Ewy GA, Freund BJ, et al. Cardiorespiratory alterations consequent to endurance exercise training during chronic beta-adrenergic blockade with atenolol and propranolol. Am J Cardiol. 1985; 55:142D–8D.

9. Ades PA, Brammell HL, Greenberg JH, Horwitz LD. Effect of beta blockade and intrinsic sympathomimetic activity on exercise performance. Am J Cardiol. 1984; 54:1337–41.

10. Kelly JG. Choice of selective versus nonselective beta blockers: implications for exercise training. Am J Cardiol. 1985; 55:162D–6D.

11. Hunter AM, St Clair Gibson A, Derman WE, Lambert M, Dennis SC, Noakes TD. The effect of selective beta1-blockade on EMG signal characteristics during progressive endurance exercise. Eur J Appl Physiol. 2002; 88:275–81.

12. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation. 2001; 104:1694–740.

13. Pollock ML, Lowenthal DT, Foster C, et al. Acute and chronic responses to exercise in patients treated with beta blockers. J Cardiopulm Rehabil. 1991; 11:132–44.

14. Leren P. Effect of alpha- and beta-blocker therapy on blood lipids: European experience. Am J Med. 1984; 76:67–71.

15. Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J. 1985; 109:1192–6.

16. Frick MH, Cox DA, Himanen P, et al. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension. Am J Cardiol. 1987; 59:61G–7G.

17. Karvonen MJ, Kentala E, Mustala O. The effects of training on heart rate; a longitudinal study. Ann Med Exp Biol Fenn. 1957; 35:307–15.

18. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335:1001–9.

19. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med. 2001; 345:892–902.

20. Laukkanen JA, Kurl S, Salonen R, Rauramaa R, Salonen JT. The predictive value of cardiorespiratory fitness for cardiovascular events in men with various risk profiles: a prospective population-based cohort study. Eur Heart J. 2004; 25:1428–37.

21. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002; 346:793–801.

22. Leren P, Foss PO, Helgeland A, Hjermann I, Holme I, Lund-Larsen PG. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet. 1980; 2:4–6.

23. Sun Y. Study of exercise and serum lipids in puberty. Zhonghua Liu Xing Bing Xue Za Zhi. 1991; 12:193–6.